carmen puliafito

We discuss new treatment options and clinical trials for radiation retinopathy with Prithvi Mruthyunjaya MD Professor of Ophthalmology, Stanford Medical School, Director of Ocular Oncology, Byers Eye Institute.

We examine the role of sub retinal fluid in the treatment of neovascular AMD with Dr. David Sarraf, Professor of Ophthalmology, UCLA Stein Eye Institute.

We discuss a phase I study examining the effect of plasma kvllikrein inhibition on diabetic macular edema with Dr. Arshad Khanani, Sierra Eye Associates, University of Nevada Reno.

We discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.

We review the results of the KS-301 wet macular degeneration trial with Dr. Carl Regillo,
Chief of the Retina Service at Wills Eye Hospital

Phase I results of suprachoroidal delivery of a gene vector in treating neovascular AMD are promising. A discussion with Nikolas London, MD from  Retina Consultant Group in San Diego CA & Scripps Memorial Hospital La Jolla. 

We examine the role of residual IRF and SRF in visual acuity results in treating nAMD. Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida reviews the results of the Hawk and Harrier trials.

We discuss the newly approved Xipere system for suprachoroidal administration of triamcinolone for treatment of macular edema associated with uveitis with Dr. Steven Yeh

We discuss with David Lally, MD   Springfield, Ma. Assistant Professor at University of Massachusetts and Tufts the use of elamipretide, a novel agent which acts at the level of the mitochondria in the treatment of geographic atrophy.

We review surgical techniques for sub retinal gene therapy with Dr. Lejla Vajzovic.

Dr. Yasha Modi, Associate Professor of Ophthalmology at the NYU Langone Medical Center provides an evidence based review of management of retinal venous occlusion.

We discuss the use of a cooling probe as primary anesthesia for intravitreal injection with Ajay Kuriyan, MD, Associate Professor of Ophthalmology, Wills Eye Hospital.

We discuss blockade of complement component C1q as a novel treatment for geographic atrophy with Donald Fong, MD, Vice President Ophthalmology Clinical Development, Annexon.

We discuss clinical trials using CNTF to treat MacTel Type 2 with Dr. John Pollack, Chief Medical Officer of Neurotech Pharmaceuticals.

Dr. Robert Avery of California Retina Consultants reviews the latest status of gene therapy for AMD and DR.

Many drugs are currently being investigated in attacking or supplementing the complement cascade for the treatment of geographic atrophy. We review, with the help of Dr. Johanna Seddon, Professor of Ophthalmology, University of Massachusetts Medical Center the basic biology that underlies these treatments, and assess their clinical potential.

Dr. Linda Lam, Professor of Ophthalmology at the USC Roski Eye Institute talks about augmented reality for low vision and unique surgical applications.

A Real World Clinical Trial Employing AI

Dr. Anat Loewenstein presents data demonstrating the effectiveness of the Notal Home OCT System with artificial intelligence for real world monitoring of eyes undergoing anti-VEGF therapy.

Diana Do, MD, Professor of Ophthalmology, Vice Chair Clinical Affairs, Department of Ophthalmology, Stanford University, Byers Eye Institute.

In this episode, Dr. David Boyer discusses a Phase 2 trial studying intravitreal injection of retinal progenitor cells for treatment of eyes with retinitis pigmentosa.